Vomitinib is not useful for Her2 gene mutations. Vomitinib is a new 3rd representative of the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), which mainly targets EGFR-sensitive mutations and EGFRT790M-resistant mutations, inhibiting their activity while blocking non-selective metabolites, thus playing a therapeutic effect, and does not target the HER2 gene, so it does not play a therapeutic role in patients with Her2 gene mutations. It does not target the HER2 gene and therefore has no therapeutic effect on patients with Her2 gene mutations. Vomitinib in the process of medication, patients may appear transaminase elevation, upper respiratory tract infection, cough and other adverse reactions, must do a good job of targeted monitoring, such as the seriousness of the situation need to carry out timely targeted treatment, if necessary, also need to suspend the treatment or replacement of drugs.